ERBB2 and breast cancer: Among these candidates, CPTZ8 (Figure 6) demonstrated superior HER2‐binding affinity, as validated by surface plasmon resonance assays and competitive binding studies in HER2‐positive (SK‐BR‐3) and HER2‐negative (MDA‐MB‐231) breast cancer cell lines [64].